International Society for the Study of Women's Sexual Health

NEWS

Flibanserin recommended for approval by the FDA Advisory Committee Panel

Dear ISSWSH members,
It is with great excitement that I share the announcement that flibanserin, a drug for hypoactive sexual desire disorder (HSDD) developed by Sprout Pharmaceuticals, was recommended for approval by the FDA Advisory Committee Panel on June 4, 2015.

This event opens the door for the first treatment for women suffering from HSDD, but more importantly sends the message that the FDA is now willing to entertain new drug applications from other companies. We are optimistic that this occurrence will instigate more research and eventually other therapeutic options. We also offer deep gratitude to many of our members who played a key role in this decision by voting as members of the FDA Advisory Panel, speaking as presenters on behalf of the sponsor, providing testimony during the Open Public Hearing, and caring for patients who also spoke at the Hearing.  

As a multidisciplinary, scientific organization dedicated to research, clinical practice, and education, we are poised to develop and disseminate clinical practice guidelines regarding screening, diagnosis, and management strategies. Through our robust infrastructure of educational programs, we will ensure appropriate, safe, and selective treatment of HSDD with flibanserin when final approval comes.

Most sincerely,
Sharon J. Parish, MD, IF
ISSWSH President, 2014-2016

Save the Date


ISSWSH Fall Course 2017

  November 2-5, 2017  219 days left
  DoubleTree Hilton Hotel, Scottsdale, AZ - USA
Read more...


ISSWSH Annual Meeting 2018

  February 8-11, 2018  317 days left
  Hilton San Diego on Mission Bay
San Diego, CA, USA

Read more...

Latest Tweets

Sexual Communication Patterns & the Sexual and Relational Adjustment of Couples Coping With Provoked Vestibulodynia https://t.co/HwxbWUfhf5 ISSWSH
Important to counsel partners of men who had radical prostatectomy https://t.co/M4jQugBqJr ISSWSH
Hormonal Contraceptive Use During Relationship Formation and Sexual Desire During Pregnancy https://t.co/2jUKtz3il0 ISSWSH

Contact Details

ISSWSH Executive Office
PO Box 1233
Lakeville, MN 55044
USA

Phone: +1 (952) 683 9025
Fax: +1 (612) 808 0491
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.